2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1717

Endothelial to Mesenchymal Transition Contributes to the Development of Pulmonary Vasculopathy in Systemic Sclerosis PAH
Abstract Number: 1710

Endothelin-1 Is a Downstream Mediator of Profibrotic Effects by Transforming Growth Factor-β1 in Systemic Sclerosis Skin Fibroblasts
Abstract Number: 774

Endothelin-1 Synergistically Increases TGF-β-Induced Hif1α Expression Under Normoxic Conditions during Endothelial-to-Mesenchymal Transition in Murine Endothelial Cells. a Novel Mechanism for the Fibrogenic Effects of Endothelin
Abstract Number: 649

Enhance Translatability Using Multi-Modality Disease Evaluation Approach in Lupus Model
Abstract Number: 2362

Enhanced Efficacy of Dexamethose with Synovial Fibroblast Targeted Micelles in a Collagen-Induced Arthritis Mouse Model
Abstract Number: 2725

Enhanced Expression of CCL25 to Facilitate Increased Numbers of CCR9-Expressing Tfh-like Cells in Salivary Glands of Primary Sjögren’s Syndrome Patients
Abstract Number: 1223

Enhancement of Proinflammatory Cytokine Production By Uric Acid in Human Cells Via Down Regulation of IL-1Ra
Abstract Number: 275

Environmental Risk Factors and Development of Juvenile Idiopathic Arthritis
Abstract Number: 1758

Environmental Risk Factors for Granulomatous Polyangiitis (GPA): Southern Hemisphere Similar to Northern Hemisphere
Abstract Number: 1258

Enzyme-Linked Immunosorbent Assays for Detection of Anti-Transcriptional Intermediary Factor-1 Gamma and Anti-Mi-2 Autoantibodies in Dermatomyositis: Utility and Crossreactivity
Abstract Number: 2211

Epidemiologic and Clinical Features of Patients with Adult and Juvenile Dermatomyositis, Polymyositis and Inclusion Body Myositis from Myovision, a National Myositis Patient Registry
Abstract Number: 1269

Epidemiology and Characteristics of Antisynthetase Syndrome in the African Descent Population of Martinique
Abstract Number: 60

Epidemiology of Polymyalgia Rheumatica in Korea
Abstract Number: 2879

Epigallocatechin-3-Gallate (EGCG) Suppresses IL-1β-Induced IL-6 and IL-8 Synthesis By Selectively Inhibiting TAK1 Activation in Human Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 623

Epigenetic Studies in Maternally Versus Paternally Transmitted Psoriatic Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].